Samoh Pharm cuts Aminologics stake to 37.03% from 39.40% - filing

By Public Technologies
  • Samoh Pharm disclosed a change in its ownership of Aminologics securities, with total holdings slipping to 36,787,758 units on Sept. 30, 2026.
  • Stake based on specific securities fell to 37.03% from 39.40% in the prior filing dated Sept. 10, 2025.
  • Common shareholding stayed at 26,783,244 shares, though the common-stock stake edged down to 29.98% from 30.39%.
  • Convertible bond holdings rose to 10,004,514 from 4,779,860, reflecting a call option exercise tied to the 4th convertible bond.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aminologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001000613), on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.